GoAI
Get started
Prime Medicine, Inc. logo

Prime Medicine, Inc.

PRME

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.39

+$0.15 · +4.63%

Aug 21, 4:00 PM ET

PRME company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

30

Expensive

Momentum

63

Gaining

Sentiment

60

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Allan Reine
Listed since
Oct 20, 2022
Employees
146

Market position

Day range

Current $3.39

52-week range

Current $3.39

Open
$3.28
Previous close
$3.24
Volume
3.6M
1.2× average
Average volume
3.01M
Average daily volume
Market cap
612.29M USD
Beta
2.31
Market reference 1
50-day average
$3.2822
+3.28% above average
200-day average
$3.5562
-4.67% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
569.59M USD
P/E (TTM)
-3.08×
P/B (TTM)
15.09×
P/S (TTM)
150.33×
EV / EBITDA
-2.91×
Earnings yield
-38.97%
Free cash flow yield
-32.37%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-1025.61%
Operating margin
-4824.94%
Net margin
-4613.11%
Return on equity
-166.41%
Return on assets
-58.69%
Return on invested capital
-66.48%

Financial health

Debt / equity
2.83×
Current ratio
4.84×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends789%-1966%-4721%-7476%Gross margin, FY2024: 100.00%Gross margin, FY2025: -58.05%Operating margin, FY2024: -6787.36%Operating margin, FY2025: -4498.06%Net margin, FY2024: -6566.61%Net margin, FY2025: -4342.44%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 -58.05%. Operating margin FY2024 -6787.36%. Operating margin FY2025 -4498.06%. Net margin FY2024 -6566.61%. Net margin FY2025 -4342.44%.

Income trends

Revenue

4.63M USD+55.28%

Operating income

−208.35M USD-2.91%

Net income

−201.14M USD-2.69%
Income trends across reported periods25.93M USD−59.26M USD−144.46M USD−229.65M USDRevenue, FY2024: 2.98M USDRevenue, FY2025: 4.63M USDOperating income, FY2021: −84.47M USDOperating income, FY2022: −116.54M USDOperating income, FY2023: −204.79M USDOperating income, FY2024: −202.47M USDOperating income, FY2025: −208.35M USDNet income, FY2021: −165.37M USDNet income, FY2022: −121.82M USDNet income, FY2023: −198.13M USDNet income, FY2024: −195.88M USDNet income, FY2025: −201.14M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 2.98M USD. Revenue FY2025 4.63M USD. Operating income FY2021 −84.47M USD. Operating income FY2022 −116.54M USD. Operating income FY2023 −204.79M USD. Operating income FY2024 −202.47M USD. Operating income FY2025 −208.35M USD. Net income FY2021 −165.37M USD. Net income FY2022 −121.82M USD. Net income FY2023 −198.13M USD. Net income FY2024 −195.88M USD. Net income FY2025 −201.14M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.63M USD2.98M USD———
Cost of goods sold7.32M USD————
Gross profit−2.69M USD2.98M USD———
Research and development160.64M USD155.29M USD147.91M USD86.73M USD70.55M USD
Selling, general, and administrative52.35M USD50.16M USD43.39M USD29.82M USD13.92M USD
Operating expenses205.66M USD205.45M USD204.79M USD116.54M USD84.47M USD
Interest income4.15M USD3.52M USD———
Depreciation and amortization5.38M USD6.13M USD4.65M USD2.22M USD568K USD
Operating income−208.35M USD−202.47M USD−204.79M USD−116.54M USD−84.47M USD
Net income−201.14M USD−195.88M USD−198.13M USD−121.82M USD−165.37M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-6.06%
11 comparable reports
Latest EPS result
-0.24
Estimate -0.26 · Beat by 6.70%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.19-0.27-0.36-0.45Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual -0.31, estimate -0.37, surprise +16.22%, Beat. Q2 2025, reported May 8, 2025: actual -0.4, estimate -0.32, surprise -25.00%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.41, estimate -0.36, surprise -13.89%, Miss. Q4 2025, reported Nov 7, 2025: actual -0.32, estimate -0.28, surprise -14.29%, Miss. Q1 2026, reported Mar 3, 2026: actual -0.22, estimate -0.25, surprise +12.00%, Beat. Q2 2026, reported May 7, 2026: actual -0.28, estimate -0.24, surprise -16.67%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.24, estimate -0.257, surprise +6.70%, Beat. Q4 2026, reported Nov 6, 2026: actual —, estimate -0.23, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.26M5.08M2.9M715.7KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 2.18M USD, estimate 6.78M USD, surprise -67.82%, Miss. Q2 2025, reported May 8, 2025: actual 1.45M USD, estimate 2.33M USD, surprise -37.69%, Miss. Q3 2025, reported Aug 7, 2025: actual 1.12M USD, estimate 2.8M USD, surprise -60.19%, Miss. Q4 2025, reported Nov 7, 2025: actual 1.23M USD, estimate 2.05M USD, surprise -40.28%, Miss. Q1 2026, reported Mar 3, 2026: actual 842K USD, estimate 1.29M USD, surprise -34.60%, Miss. Q2 2026, reported May 7, 2026: actual 856K USD, estimate 2.33M USD, surprise -63.24%, Miss. Q3 2026, reported Aug 6, 2026: actual 1.15M USD, estimate 2.25M USD, surprise -48.74%, Miss. Q4 2026, reported Nov 6, 2026: actual —, estimate 1.25M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.67

126.25% upside
Past 12 months12-month forecastHigh $9.00Average $7.67Low $6.00

Recent analyst actions

9 institutions
BMO CapitalmaintainOutperform
JMP SecuritiesmaintainMarket Outperform
Citizens Capital MarketsmaintainMarket Outperform

PRME peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research PRME

research.disclaimer